MAR 14, 2016 12:34 PM PDT

Drug Duo Dramatically Shrunk Breast Tumors in 11 Days

WRITTEN BY: Xuan Pham
In a ground-breaking “surprise” finding, UK doctors announced a pair of drugs dramatically shrunk some breast tumors in a mere 11 days after diagnosis. The results were publicly presented at the European Breast Cancer Conference, and could have wide-reaching impacts for the treatment of breast cancers.
 
New tailored treatments for HER2 positive breast cancers on the horizon

The study was conducted to explore how drugs alter breast cancer biology in the short time between diagnosis and surgical resection. The 257 women recruited for the study were diagnosed with human epidermal growth factor receptor 2, otherwise known as HER2-positive, breast cancer. For some women who were treated with both trastuzumab (Herceptin) and lapatinib (Tyverb), doctors found little to no trace of the breast tumors when it came time to operate at day 11. The results were so remarkable that it surprised even the study surgeons, who didn’t expect to achieve such results in such a short amount of time.

"This has ground-breaking potential because it allows us to identify a group of patients who, within 11 days, have had their tumors disappear with anti-HER2 therapy alone and who potentially may not require subsequent chemotherapy," said Nigel Bundred, chief investigator and surgical oncology professor at the University of Manchester. "This offers the opportunity to tailor treatment for each individual woman."

The study included 127 women who were either given trastuzumab only, both trastuzumab and lapatinib, or no drugs at all. For women who took the drug duo, researchers found 87 percent had significant decrease in the number of cancer cells. Remarkably, 11 percent of these women had no active cancer cells at all. Another 17 percent showed marked reduction in tumor size from 1 to 3 centimeters to less than 5 millimeters in diameter.

The drugs are not new and they both target the HER2 protein. Herceptin is known to work on the surface of cancer cells while lapatinib penetrates inside the cell to disable HER2. As part of current treatment for HER2 positive breast cancer, surgery is the first step, followed by chemotherapy with Herceptin.

These results suggest that some patients may not need chemotherapy if the drugs are administered quickly enough after diagnosis. It may also recalibrate how quickly doctors can assess response in patients after treatment, as this study revealed it can be done in as short as 11 days.

However, the doctors are cautiously optimistic, noting that these astonishing results need to be confirmed in more trials. Given that HER2 positive breast cancers have a high penchant for recurring, the additional trials are absolutely vital to establish whether or not chemotherapy can be skipped. "We would have to be very clear we're not taking a backwards step and increasing the risk of relapse," said Judith Bliss, co-investigator of the study.
 

Additional source: European Cancer Organization
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 14, 2020
Cancer
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
SEP 14, 2020
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting ...
SEP 21, 2020
Cancer
Black women have delayed and longer breast cancer treatment
SEP 21, 2020
Black women have delayed and longer breast cancer treatment
A study led by UNC Lineberger Comprehensive Cancer Center researchers has quantified the healthcare inequities in cancer ...
OCT 26, 2020
Chemistry & Physics
Fighting mesothelioma with gold nanotubes
OCT 26, 2020
Fighting mesothelioma with gold nanotubes
New research published in the journal Small details how gold nanotubes could be used to treat mesothelioma cancer. ...
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
NOV 18, 2020
Genetics & Genomics
Choosing an NGS workflow: What are you looking for?
NOV 18, 2020
Choosing an NGS workflow: What are you looking for?
  It’s easy to be overwhelmed by the number of workflows that are available for NGS. How do you choose? While ...
NOV 19, 2020
Cancer
New technique to synthesize phenazines offers hope for cancer treatments
NOV 19, 2020
New technique to synthesize phenazines offers hope for cancer treatments
Research from Tokyo University of Science investigators highlights new accomplishments in the fight against cancer. The ...
Loading Comments...